Trial Profile
An Open-Label, Single-Center, Phase 1 Study to Determine the Pharmacokinetics of Single Intravenous Dose of Vedolizumab 300 mg in Healthy Adult Chinese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Sep 2019
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Coeliac disease; Crohn's disease; Graft-versus-host disease; Malignant melanoma; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Takeda
- 29 Aug 2018 Status changed from recruiting to completed.
- 16 Mar 2018 Status changed from not yet recruiting to recruiting.
- 11 Jan 2018 Planned initiation date changed from 21 Nov 2017 to 1 Mar 2018.